Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Non-Current Debt (2016 - 2025)

Ironwood Pharmaceuticals' Non-Current Debt history spans 10 years, with the latest figure at $385.0 million for Q4 2025.

  • For Q4 2025, Non-Current Debt changed 0.0% year-over-year to $385.0 million; the TTM value through Dec 2025 reached $385.0 million, changed 0.0%, while the annual FY2025 figure was $385.0 million, 0.0% changed from the prior year.
  • Non-Current Debt for Q4 2025 was $385.0 million at Ironwood Pharmaceuticals, roughly flat from $385.0 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $425.0 million in Q2 2024 and bottomed at $275.0 million in Q1 2024.
  • The 3-year median for Non-Current Debt is $385.0 million (2024), against an average of $368.2 million.
  • The largest YoY upside for Non-Current Debt was 40.0% in 2025 against a maximum downside of 9.41% in 2025.
  • A 3-year view of Non-Current Debt shows it stood at $300.0 million in 2023, then grew by 28.33% to $385.0 million in 2024, then changed by 0.0% to $385.0 million in 2025.
  • Per Business Quant, the three most recent readings for IRWD's Non-Current Debt are $385.0 million (Q4 2025), $385.0 million (Q3 2025), and $385.0 million (Q2 2025).